Creative Medical Technology (CELZ) Set to Announce Earnings on Friday

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) is anticipated to release its resultson Friday, November 6th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, analysts expect Creative Medical Technology to post ($1.18) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

Creative Medical Technology Trading Down 5.8%

NASDAQ:CELZ opened at $0.68 on Friday. Creative Medical Technology has a 1-year low of $0.62 and a 1-year high of $4.72. The stock has a fifty day simple moving average of $0.94 and a 200 day simple moving average of $1.58.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wall Street Zen upgraded Creative Medical Technology from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Roth Capital reaffirmed a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. Finally, Weiss Ratings cut shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Creative Medical Technology currently has an average rating of “Hold”.

View Our Latest Stock Analysis on Creative Medical Technology

About Creative Medical Technology

(Get Free Report)

Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.

The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.

Further Reading

Earnings History for Creative Medical Technology (NASDAQ:CELZ)

Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.